About resTORbio, Inc.resTORbio, Inc., a subsidiary of PureTech Health (LSE: PRTC; www.puretechhealth.com), is developing medicines to treat aging-related diseases and conditions. resTORbio’s lead program is targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio’s lead program is built upon two Phase 2 clinical studies demonstrating promising safety and efficacy results in almost 500 hundred elderly subjects. resTORbio is pursuing a pragmatic clinical development plan addressing areas of key unmet medical need in the aging population.
CEO: Chen Schor
CMO: Joan Mannick
Tweets by resTORbio, Inc.
35 articles with resTORbio, Inc.
resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness
resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1)
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Boston-based resTORbio, which was spun out of Novartis in April 2017, announced positive topline results from its Phase IIb clinical trial of RTB101 in patients with respiratory tract infections (RTIs).
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
The shares commenced trading on the NASDAQ Global Select Market on January 26, 2018 under the ticker symbol “TORC.”
The offering is expected to close on January 30, 2018, subject to customary closing conditions.
resTORbio is developing novel therapies to improve immune function in the elderly.
resTORbio announced that Lynne Sullivan, Senior Vice President of Finance for Biogen, Inc. has joined the resTORbio board of directors as an independent director.
Three biotech companies want to start out the new year with a new start.
resTORbio announced that Paul Fonteyne, President and CEO of Boehringer Ingelheim USA, has joined the resTORbio board of directors as an independent director.
resTORbio Files Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
resTORbio today announced that it has previously confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock.
This financing brings the total capital raised this year to $65 million, including a $25 million Series A financing that was completed earlier this year.
resTORbio Advances to Part 2 of a Phase IIb Clinical Study of RTB101 Immunotherapy Following Unanimous Recommendation of Independent Data Monitoring Committee Overseeing the Study
The Phase 2b clinical study is designed to assess the safety, tolerability and efficacy of 16 weeks of treatment with RTB101 alone or in combination with everolimus as compared to placebo in reducing the percentage of elderly individuals with respiratory tract infections.